By Chris Houchin
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), speaks with Chris Houchin, Partner at Guidehouse, in a video interview about leveraging AI at the agency, developments in data-driven healthcare, and improving communication regarding frontier topics like explainability, data integrity, bias, and data security.
Speaking about the FDA’s approach to leveraging AI, Marks says that the agency is open to the use of AI but according to best practices. The application is being seen across multiple areas, from manufacturing to post-market surveillance. He mentions that the agency is using AI in manufacturing particularly in the complex biologics product area which involves multiple critical quality attributes that need to be checked during manufacturing.
Watch the full video below.
Complexity demands a trusted guide with the unique expertise and cross-sector versatility to deliver unwavering success. We work with organizations across regulated commercial and public sectors to catalyze transformation and pioneer new directions for the future.